Annexin A5-DM1 protein-drug conjugate for the treatment of triple-negative breast cancer.

This article discusses a potential treatment for triple-negative breast cancer (TNBC), which is a particularly aggressive and metastatic form of breast cancer. The researchers propose using a protein-drug conjugate called ANXA5-DM1, which targets a biomarker called phosphatidylserine (PS) found on TNBC cells. The conjugate was found to be highly cytotoxic to TNBC cells while sparing healthy breast cells. Additionally, it induced immunogenic cell death (ICD), which is a desirable outcome for cancer treatment. The study provides evidence for the potential effectiveness of ANXA5-DM1 as a targeted therapy for TNBC. [Extracted from the article]